| Title |
PEGylation of Interferon-β-1a
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/11596970-000000000-00000 |
| Pubmed ID | |
| Authors |
Bernd C. Kieseier, Peter A. Calabresi |
| Abstract |
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Spain | 1 | 2% |
| United States | 1 | 2% |
| Portugal | 1 | 2% |
| Unknown | 39 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 21% |
| Researcher | 6 | 14% |
| Student > Bachelor | 5 | 12% |
| Other | 5 | 12% |
| Student > Master | 5 | 12% |
| Other | 6 | 14% |
| Unknown | 7 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 33% |
| Agricultural and Biological Sciences | 10 | 23% |
| Neuroscience | 4 | 9% |
| Chemical Engineering | 2 | 5% |
| Sports and Recreations | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 10 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2020.
All research outputs
#5,446,629
of 25,373,627 outputs
Outputs from CNS Drugs
#512
of 1,387 outputs
Outputs of similar age
#38,817
of 187,950 outputs
Outputs of similar age from CNS Drugs
#164
of 541 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,387 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,950 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.